Growth kinetics and chemoprevention of aberrant crypts in the rat colon

Michael J Wargovich, C. Harris, C. D. Chen, C. Palmer, V. E. Steele, G. J. Kelloff

Research output: Contribution to journalArticle

Abstract

Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. In a characterization study, we have established the kinetics of AC growth and development over a period of 20 d following injection of rats with the carcinogen azoxymethane (AOM). AC are not present at 5 d post-injection, but are a constant feature at 10 d and thereafter. Multiple AC, presumably clonal, begin to evolve at 10 d and are consistent by 20 d, forming incipient microadenomata. We have examined 20 candidate chemopreventive agents for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were BHA, DFMO, quercetin, diallyl sulfide, 18β-glycyrrhetinic acid, and ascohbyl palmitate. In a postinitiation study, the differentiating agent sodium butyrate was ineffective, but piroxicam was highly effective in modulating AC growth. Further, piroxicam inhibited AC development at all stages of growth from single to polycryptal clusters of AC. The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.

Original languageEnglish (US)
Pages (from-to)51-54
Number of pages4
JournalJournal of Cellular Biochemistry
Volume50
Issue numberSUPPL. G
StatePublished - 1992
Externally publishedYes

Fingerprint

Growth kinetics
Chemoprevention
Azoxymethane
Piroxicam
Rats
Colon
Colonic Neoplasms
Injections
Growth
Glycyrrhetinic Acid
Butylated Hydroxyanisole
Butyric Acid
Palmitates
Methylene Blue
Quercetin
Growth and Development
Carcinogens
Staining and Labeling
Diet
Sensitivity and Specificity

Keywords

  • aberrant crypts
  • azoxymethane
  • chemoprevention
  • colorectal cancer
  • intermediate biomarker
  • NSAID
  • piroxicam

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Wargovich, M. J., Harris, C., Chen, C. D., Palmer, C., Steele, V. E., & Kelloff, G. J. (1992). Growth kinetics and chemoprevention of aberrant crypts in the rat colon. Journal of Cellular Biochemistry, 50(SUPPL. G), 51-54.

Growth kinetics and chemoprevention of aberrant crypts in the rat colon. / Wargovich, Michael J; Harris, C.; Chen, C. D.; Palmer, C.; Steele, V. E.; Kelloff, G. J.

In: Journal of Cellular Biochemistry, Vol. 50, No. SUPPL. G, 1992, p. 51-54.

Research output: Contribution to journalArticle

Wargovich, MJ, Harris, C, Chen, CD, Palmer, C, Steele, VE & Kelloff, GJ 1992, 'Growth kinetics and chemoprevention of aberrant crypts in the rat colon', Journal of Cellular Biochemistry, vol. 50, no. SUPPL. G, pp. 51-54.
Wargovich MJ, Harris C, Chen CD, Palmer C, Steele VE, Kelloff GJ. Growth kinetics and chemoprevention of aberrant crypts in the rat colon. Journal of Cellular Biochemistry. 1992;50(SUPPL. G):51-54.
Wargovich, Michael J ; Harris, C. ; Chen, C. D. ; Palmer, C. ; Steele, V. E. ; Kelloff, G. J. / Growth kinetics and chemoprevention of aberrant crypts in the rat colon. In: Journal of Cellular Biochemistry. 1992 ; Vol. 50, No. SUPPL. G. pp. 51-54.
@article{287b0cd8e2fa41c58593e135a5da92e7,
title = "Growth kinetics and chemoprevention of aberrant crypts in the rat colon",
abstract = "Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. In a characterization study, we have established the kinetics of AC growth and development over a period of 20 d following injection of rats with the carcinogen azoxymethane (AOM). AC are not present at 5 d post-injection, but are a constant feature at 10 d and thereafter. Multiple AC, presumably clonal, begin to evolve at 10 d and are consistent by 20 d, forming incipient microadenomata. We have examined 20 candidate chemopreventive agents for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were BHA, DFMO, quercetin, diallyl sulfide, 18β-glycyrrhetinic acid, and ascohbyl palmitate. In a postinitiation study, the differentiating agent sodium butyrate was ineffective, but piroxicam was highly effective in modulating AC growth. Further, piroxicam inhibited AC development at all stages of growth from single to polycryptal clusters of AC. The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.",
keywords = "aberrant crypts, azoxymethane, chemoprevention, colorectal cancer, intermediate biomarker, NSAID, piroxicam",
author = "Wargovich, {Michael J} and C. Harris and Chen, {C. D.} and C. Palmer and Steele, {V. E.} and Kelloff, {G. J.}",
year = "1992",
language = "English (US)",
volume = "50",
pages = "51--54",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. G",

}

TY - JOUR

T1 - Growth kinetics and chemoprevention of aberrant crypts in the rat colon

AU - Wargovich, Michael J

AU - Harris, C.

AU - Chen, C. D.

AU - Palmer, C.

AU - Steele, V. E.

AU - Kelloff, G. J.

PY - 1992

Y1 - 1992

N2 - Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. In a characterization study, we have established the kinetics of AC growth and development over a period of 20 d following injection of rats with the carcinogen azoxymethane (AOM). AC are not present at 5 d post-injection, but are a constant feature at 10 d and thereafter. Multiple AC, presumably clonal, begin to evolve at 10 d and are consistent by 20 d, forming incipient microadenomata. We have examined 20 candidate chemopreventive agents for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were BHA, DFMO, quercetin, diallyl sulfide, 18β-glycyrrhetinic acid, and ascohbyl palmitate. In a postinitiation study, the differentiating agent sodium butyrate was ineffective, but piroxicam was highly effective in modulating AC growth. Further, piroxicam inhibited AC development at all stages of growth from single to polycryptal clusters of AC. The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.

AB - Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. In a characterization study, we have established the kinetics of AC growth and development over a period of 20 d following injection of rats with the carcinogen azoxymethane (AOM). AC are not present at 5 d post-injection, but are a constant feature at 10 d and thereafter. Multiple AC, presumably clonal, begin to evolve at 10 d and are consistent by 20 d, forming incipient microadenomata. We have examined 20 candidate chemopreventive agents for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were BHA, DFMO, quercetin, diallyl sulfide, 18β-glycyrrhetinic acid, and ascohbyl palmitate. In a postinitiation study, the differentiating agent sodium butyrate was ineffective, but piroxicam was highly effective in modulating AC growth. Further, piroxicam inhibited AC development at all stages of growth from single to polycryptal clusters of AC. The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.

KW - aberrant crypts

KW - azoxymethane

KW - chemoprevention

KW - colorectal cancer

KW - intermediate biomarker

KW - NSAID

KW - piroxicam

UR - http://www.scopus.com/inward/record.url?scp=0026440091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026440091&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 51

EP - 54

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. G

ER -